Phaos Technology Holdings (Cayman) (POAS) Short term Debt (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) posted Short term Debt of $56951.0 for Q4 2025, up 36.89% on a QoQ basis from $41604.3 in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Short term Debt (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman)'s Short term Debt history runs 2 years deep, the most recent figure standing at $56951.0 for Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $56951.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $56951.0 (changed N/A YoY) and the FY2025 annual result came in at $41642.4, down 87.27% from the prior year.
Short term Debt was $56951.0 for Q4 2025 at Phaos Technology Holdings (Cayman), up from $41604.3 in the prior quarter.
Across five years, Short term Debt topped out at $327030.0 in Q2 2024 and bottomed at $41604.3 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.81 Bn	175.52 Bn	6.27 Bn
2	Stryker	128.98 Bn	126.10 Bn	3.81 Bn
3	Medtronic	108.67 Bn	99.45 Bn	6.41 Bn
4	Boston Scientific	68.36 Bn	66.91 Bn	3.61 Bn
5	Edwards Lifesciences	47.70 Bn	44.03 Bn	1.29 Bn
6	Dexcom	28.67 Bn	27.55 Bn	750.30 Mn
7	GE HealthCare Technologies	28.55 Bn	26.27 Bn	1.98 Bn
8	Smith & Nephew	26.97 Bn	26.40 Bn	-
9	Koninklijke Philips	25.45 Bn	22.33 Bn	2.07 Bn
10	Phaos Technology Holdings (Cayman)	6.17 Mn	6.12 Mn	-

Download Data